Atossa Therapeutics, Inc. – NASDAQ:ATOS

Atossa Therapeutics stock price today

$0.76
-0.22
-22.54%
Financial Health
0
1
2
3
4
5
6
7
8
9

Atossa Therapeutics stock price monthly change

-25.11%
month

Atossa Therapeutics stock price quarterly change

-25.11%
quarter

Atossa Therapeutics stock price yearly change

+8.71%
year

Atossa Therapeutics key metrics

Market Cap
123.76M
Enterprise value
N/A
P/E
-3.52
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
794.21
PEG ratio
0.21
EPS
-0.23
Revenue
N/A
EBITDA
-28.24M
Income
-29.69M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Atossa Therapeutics stock price history

Atossa Therapeutics stock forecast

Atossa Therapeutics financial statements

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Profit margin
Jun 2023 0 -9.83M
Sep 2023 0 -6.22M
Dec 2023 0 -7.75M
Mar 2024 0 -5.87M
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Analyst Estimates
Dec 2023 0 -7.75M
Mar 2024 0 -5.87M
Sep 2025 0 -7.51M
Dec 2025 0 -7.51M
  • Analysts Price target

  • Financials & Ratios estimates

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Debt to assets
Jun 2023 108355000 3.47M 3.21%
Sep 2023 101695000 3.44M 3.39%
Dec 2023 96252000 5.23M 5.44%
Mar 2024 91087000 5.32M 5.85%
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Cash Flow
Jun 2023 -4.46M -13K 0
Sep 2023 -3.88M -1K -1.47M
Dec 2023 -5.57M 0 0
Mar 2024 -4.69M -6K 204K

Atossa Therapeutics alternative data

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Employee count
Aug 2023 11
Sep 2023 11
Oct 2023 11
Nov 2023 11
Dec 2023 11
Jan 2024 11
Feb 2024 11
Mar 2024 11
Apr 2024 11
May 2024 12
Jun 2024 12
Jul 2024 12

Atossa Therapeutics other data

100.00% 0.00%
of ATOS is owned by hedge funds
23.26M -12.59M
shares is hold by hedge funds

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Insider trades (number of shares)
Period Buy Sel
Jun 2023 50000 0
Nov 2023 0 50000
Apr 2024 25000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
FINN JONATHAN director
Common Stock 25,000 $1.77 $44,250
Sale
WEAVER GREGORY L director, officer: Former EVP, ..
Common Stock 50,000 $0.65 $32,500
Purchase
WEAVER GREGORY L director, officer: EVP & CFO
Common Stock 50,000 $0.97 $48,500
Option
WEAVER GREGORY L director
Stock Option (right to buy) 70,000 $1.7 $119,000
Sale
WEAVER GREGORY L director
Common Stock 107,497 $5.58 $599,833
Option
WEAVER GREGORY L director
Common Stock 70,000 $1.7 $119,000
Option
WEAVER GREGORY L director
Common Stock 45,000 $2.52 $113,400
Option
WEAVER GREGORY L director
Common Stock 45,000 $2.38 $107,100
Option
WEAVER GREGORY L director
Common Stock 4,581 $5.64 $25,837
Purchase
CHEN SHU-CHIH director
Series B Convertible Preferred Stock 8 $3.52 $28
Patent
Application
Filling date: 20 Jan 2022 Issue date: 4 Aug 2022
Application
Filling date: 2 Jul 2020 Issue date: 9 Jun 2022
Application
Filling date: 11 Mar 2019 Issue date: 4 Mar 2021
Application
Filling date: 20 Dec 2018 Issue date: 7 Jan 2021
Application
Filling date: 10 Sep 2018 Issue date: 27 Aug 2020
Application
Filling date: 10 Sep 2018 Issue date: 9 Jul 2020
Application
Filling date: 10 Sep 2018 Issue date: 2 Jul 2020
Insider Compensation
Dr. Steven C. Quay (1951) Chairman, Chief Executive Officer & Pres $944,570
Mr. Kyle Guse CPA, Esq., CPA (1964) Chief Financial Officer, Gen. Counsel & Sec.
$624,130
Friday, 20 December 2024
zacks.com
Thursday, 19 December 2024
globenewswire.com
Thursday, 12 December 2024
globenewswire.com
Wednesday, 11 December 2024
globenewswire.com
Tuesday, 10 December 2024
globenewswire.com
Monday, 9 December 2024
globenewswire.com
Thursday, 21 November 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Tuesday, 12 November 2024
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Monday, 4 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Monday, 28 October 2024
zacks.com
Monday, 21 October 2024
globenewswire.com
Monday, 14 October 2024
globenewswire.com
Tuesday, 1 October 2024
globenewswire.com
Thursday, 19 September 2024
zacks.com
Tuesday, 10 September 2024
globenewswire.com
Tuesday, 3 September 2024
zacks.com
globenewswire.com
Friday, 30 August 2024
zacks.com
Wednesday, 28 August 2024
globenewswire.com
Wednesday, 21 August 2024
globenewswire.com
globenewswire.com
Tuesday, 20 August 2024
globenewswire.com
Monday, 12 August 2024
globenewswire.com
Monday, 22 July 2024
globenewswire.com
Thursday, 11 July 2024
zacks.com
investorplace.com
Wednesday, 3 July 2024
investorplace.com
  • What's the price of Atossa Therapeutics stock today?

    One share of Atossa Therapeutics stock can currently be purchased for approximately $0.76.

  • When is Atossa Therapeutics's next earnings date?

    Unfortunately, Atossa Therapeutics's (ATOS) next earnings date is currently unknown.

  • Does Atossa Therapeutics pay dividends?

    No, Atossa Therapeutics does not pay dividends.

  • How much money does Atossa Therapeutics make?

    Atossa Therapeutics has a market capitalization of 123.76M.

  • What is Atossa Therapeutics's stock symbol?

    Atossa Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ATOS".

  • What is Atossa Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Atossa Therapeutics?

    Shares of Atossa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Atossa Therapeutics's key executives?

    Atossa Therapeutics's management team includes the following people:

    • Dr. Steven C. Quay Chairman, Chief Executive Officer & Pres(age: 74, pay: $944,570)
    • Mr. Kyle Guse CPA, Esq., CPA Chief Financial Officer, Gen. Counsel & Sec.(age: 61, pay: $624,130)
  • How many employees does Atossa Therapeutics have?

    As Jul 2024, Atossa Therapeutics employs 12 workers, which is 9% more then previous quarter.

  • When Atossa Therapeutics went public?

    Atossa Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 8 Nov 2012.

  • What is Atossa Therapeutics's official website?

    The official website for Atossa Therapeutics is atossatherapeutics.com.

  • Where are Atossa Therapeutics's headquarters?

    Atossa Therapeutics is headquartered at 107 Spring Street, Seattle, WA.

  • How can i contact Atossa Therapeutics?

    Atossa Therapeutics's mailing address is 107 Spring Street, Seattle, WA and company can be reached via phone at +20 65 880256.

Atossa Therapeutics company profile:

Atossa Therapeutics, Inc.

atossatherapeutics.com
Exchange:

NASDAQ

Full time employees:

12

Industry:

Biotechnology

Sector:

Healthcare

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

107 Spring Street
Seattle, WA 98104

CIK: 0001488039
ISIN: US04962H5063
CUSIP: 04962H506